Open AccessVDRA therapy is associated with improved survival in dialysis patients with serum intact PTH <=150 pg/mL: results of the Italian FARO Survey
Author(s) -
Mario Cozzolino,
Diego Brancaccio,
Giuseppe Cannella,
Piergiorgio Messa,
L. Gesualdo,
Martino Marangella,
C Lodeserto,
Marco Pozzato,
Giuseppe Rombolà,
Anna Maria Costanzo,
Umberto di Luzio Paparatti,
Sandro Mazzaferro
Publication year - 2012
Publication title -
nephrology dialysis transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.654
H-Index - 168
eISSN - 1460-2385
pISSN - 0931-0509
DOI - 10.1093/ndt/gfs108
Subject(s) - medicine , parathyroid hormone , dialysis , kidney disease , endocrinology , dialysis therapy , chronic kidney disease mineral and bone disorder , hemodialysis , end stage kidney disease , kidney , gastroenterology , urology , renal osteodystrophy , calcium
Chronic kidney disease (CKD) patients affected by mineral bone disorders (MBD) have higher rates of all-cause and cardiovascular-related mortality. Approximately, one-third of dialysis patients have low serum parathyroid hormone (PTH) levels (≤ 150 pg/mL). However, the reason why these patients have higher mortality compared to patients with normal PTH levels has not yet been fully elucidated.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom